Evidence map›Paper›PMID 42147445›Full record

ArticleMolecular therapy. Advances2026

Arrayed dual-gRNA CRISPR screening platform for

Olubankole Aladesuyi Arogundade, Katie Jing Kay Lam, Katherine A Brown, Tanya Jain, Patrick O Issagholian-Lewin, Cerianne Huang, Taylor Rae-Hudson, Kevin Briseno, Stacia K Wyman, Netravathi Krishnappa and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Olubankole Aladesuyi ArogundadeWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Katie Jing Kay LamWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Katherine A BrownWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Tanya JainWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Patrick O Issagholian-LewinWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Cerianne HuangWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Taylor Rae-HudsonInnovative Genomics Institute, Berkeley, CA 94720, USA.
Kevin BrisenoInnovative Genomics Institute, Berkeley, CA 94720, USA.
Stacia K WymanInnovative Genomics Institute, Berkeley, CA 94720, USA.
Netravathi KrishnappaInnovative Genomics Institute, Berkeley, CA 94720, USA.
Christy Ann GeorgeInnovative Genomics Institute, Berkeley, CA 94720, USA.
Kierney O'DareThe School of Medicine, Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, Wales CF10 3AT, UK.
Rosemary H C WilsonThe School of Medicine, Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, Wales CF10 3AT, UK.
Patrick van EijkThe School of Medicine, Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, Wales CF10 3AT, UK.
Simon H ReedThe School of Medicine, Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, Wales CF10 3AT, UK.
Petros GiannikopoulosInnovative Genomics Institute, Berkeley, CA 94720, USA.
Claire D ClellandWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.

Funding

Resource Core II: In Vivo CoreU19NS132303 · NINDS · UNIVERSITY OF CALIFORNIA BERKELEY · PI FYODOR D URNOV · 2023 to 2026
$19.7M
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approachesR01AG072052 · NIA · J. DAVID GLADSTONE INSTITUTES · PI CONKLIN, BRUCE R · 2024 to 2025
$1.4M
CRISPR-Cas9 editing in C9orf72 patient derived iPSCK08NS112330 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CLELLAND, CLAIRE · 2020 to 2024
$1.2M
Optimization of CRISPR genome editor and its delivery strategy for C9orf72 frontotemporal dementiaU01NS134062 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CLELLAND, CLAIRE, GONG, SHAOQIN - · 2023 to 2023
$870k
NIA NIH HHS R01 AG072052NINDS NIH HHS K08 NS112330NINDS NIH HHS U01 NS134062NINDS NIH HHS U19 NS132303
6 · The paper itself

Abstract

An intronic hexanucleotide repeat expansion in

Indexed as

allele-specificamyotrophic lateral sclerosis, ALSarrayed CRISPR gRNA screenC9orf72CRISPRdementiadual-gRNAfrontotemporal dementia, FTDgene therapyiPSCsmotor-neuron diseaserepeat expansion

Identifiers

PMID42147445
PMCPMC13175772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.